trial summary · NCT07582172
Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
Phase 2 Trial of Total Marrow and Lymphoid Irradiation (TMLI) as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplantation (PBSC-HCT) From a Match Donor With Fludarabine and Melphalan in Older Patients With Refractory Acute Myeloid Leukemia and MDS
Trial record from the TrialBase DB dataset, status RECRUITING, condition Acute Myeloid Leukemia With Complex Karyotype, sponsored by City of Hope Medical Center. Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
This phase II trial tests the effect of total marrow and lymphoid irradiation (TMLI) in combination with fludarabine and melphalan as conditioning regimen in older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome that has not responded to previous treatment (refractory) and that has come back after a period of improvement (relapsed) and are undergoing a donor (allogeneic) peripheral blood stem cell (PBSC) hematopoietic cell transplant (HCT) from a matched related or unrelated donor. HCT is the only curative treatment for high-risk patients, but the side effects related to the current conditioning treatments limit the use to younger and more fit patients. TMLI is a targeted form of total body radiation that uses intensity-modulated radiation therapy to target marrow, lymph node chains, and the spleen. It is designed to reduce radiation-associated side effects and maximize the radiation therapeutic effect. Fludarabine blocks cells from making deoxyribonucleic acid (DNA) and may kill cancer cells. It is a type of purine antagonist and a type of ribonucleotide reductase inhibitor. Melphalan is in a class of medications called alkylating agents. It may kill cancer cells by damaging their DNA and stopping them from dividing. Giving chemotherapy, such as fludarabine and melphalan, and TMLI before an allogeneic transplant helps kill cancer cells in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells to grow. When healthy stem cells from a related or unrelated donor, such as PBSC HCT, that closely match the …
Source record: https://clinicaltrials.gov/study/NCT07582172
Facts
| registry id | NCT07582172 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | PHASE2 |
| study type | INTERVENTIONAL |
| lead condition | Acute Myeloid Leukemia With Complex Karyotype |
| sponsor | City of Hope Medical Center |
| sponsor class | OTHER |
| enrollment | 35 |
| start date | 2026-11-05 |
| primary completion | 2031-11-05 |
| completion | 2031-11-05 |
| results posted | not reported |
Conditions
- Acute Myeloid Leukemia With Complex Karyotype
- Myelodysplastic Chronic Myelomonocytic Leukemia
- Myelodysplastic Syndrome
- Recurrent Acute Myeloid Leukemia
- Recurrent Myelodysplastic Chronic Myelomonocytic Leukemia
- Recurrent Myelodysplastic Syndrome
- Recurrent Secondary Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia
- Refractory Myelodysplastic Chronic Myelomonocytic Leukemia
- Refractory Myelodysplastic Syndrome
- Refractory Secondary Acute Myeloid Leukemia
Interventions
- Biospecimen Collection
- Bone Marrow Biopsy
- Computed Tomography
- Echocardiography Test
- Fludarabine Phosphate
- Melphalan
- Multigated Acquisition Scan
- Palifermin
- Peripheral Blood Stem Cell Transplantation
- Questionnaire Administration
- Sirolimus
- Tacrolimus
1 more in the dataset.
Countries
- United States
Intervention types: BIOLOGICAL, DRUG, OTHER, PROCEDURE, RADIATION
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.